AR044383A1 - Composiciones farmaceuticas de vareniclina - Google Patents
Composiciones farmaceuticas de vareniclinaInfo
- Publication number
- AR044383A1 AR044383A1 ARP040101714A ARP040101714A AR044383A1 AR 044383 A1 AR044383 A1 AR 044383A1 AR P040101714 A ARP040101714 A AR P040101714A AR P040101714 A ARP040101714 A AR P040101714A AR 044383 A1 AR044383 A1 AR 044383A1
- Authority
- AR
- Argentina
- Prior art keywords
- varenicline
- pharmaceutical compositions
- dosage forms
- storage conditions
- formyl
- Prior art date
Links
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 title abstract 3
- 229960004751 varenicline Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000007857 degradation product Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formas de dosificación farmacéutica de vareniclina, que son útiles para ayudar a dejar de fumar y que presentan una buena estabilidad en condiciones de almacenamiento. Formulaciones de vareniclina en las que las formas de dosificación que se producen a partir de ellas generan en condiciones de almacenamiento especificadas, una proporción menor que aproximadamente 4 % en una relación en peso, de los productos de degradación N-formil y N-metil derivados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47209803P | 2003-05-20 | 2003-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044383A1 true AR044383A1 (es) | 2005-09-07 |
Family
ID=33476925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101714A AR044383A1 (es) | 2003-05-20 | 2004-05-18 | Composiciones farmaceuticas de vareniclina |
Country Status (9)
Country | Link |
---|---|
US (2) | US20040235850A1 (es) |
EP (1) | EP1633358A1 (es) |
JP (1) | JP2006528237A (es) |
AR (1) | AR044383A1 (es) |
BR (1) | BRPI0410219A (es) |
CA (1) | CA2525874C (es) |
MX (1) | MXPA05012507A (es) |
TW (1) | TW200427469A (es) |
WO (1) | WO2004103372A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
CN1596128A (zh) | 2001-11-30 | 2005-03-16 | 辉瑞产品公司 | 5,7,14-三氮杂四环[10.3.1.0(2,11).0(4,9)]-十六碳-2(11)3,5,7,9-五烯的药物组合物 |
ES2708552T3 (es) | 2002-12-20 | 2019-04-10 | Niconovum Ab | Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC) |
US20080181933A1 (en) * | 2005-03-21 | 2008-07-31 | Pfizer Inc. | Chewing Gum Compositions of Varenicline |
US7534381B2 (en) * | 2005-09-14 | 2009-05-19 | Isp Investments Inc. | Process and apparatus for forming agglomerates of a powder composition of an active and binder |
AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
CA2650211A1 (en) * | 2006-04-24 | 2007-11-01 | Prizer Products Inc. | Asymmetric membranes for drug delivery devices |
WO2009027786A2 (en) * | 2007-08-29 | 2009-03-05 | Pfizer Inc. | Matrix dosage forms of varenicline |
WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
US9463190B2 (en) * | 2008-03-31 | 2016-10-11 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
US8039620B2 (en) * | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
RU2012102052A (ru) * | 2009-06-22 | 2013-11-20 | Тева Фармасьютикал Индастриз Лтд. | Твердые формы солей варениклина и способы их получения |
EA201391758A1 (ru) * | 2011-05-24 | 2014-06-30 | Тева Фармасьютикал Индастриз Лтд. | Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты |
DE102013011472A1 (de) * | 2013-07-05 | 2015-01-22 | Falk von Zitzewitz | Vareniclin zur Behandlung nicht-stoffgebundener Abhängigkeiten |
KR20180058644A (ko) * | 2016-11-24 | 2018-06-01 | 에스케이케미칼 주식회사 | 바레니클린 서방성 제제 및 이의 제조 방법 |
WO2018160043A1 (ko) * | 2017-03-03 | 2018-09-07 | 주식회사 씨티씨바이오 | 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제 |
KR102463733B1 (ko) * | 2017-06-30 | 2022-11-04 | 한미약품 주식회사 | 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물 |
US10912734B2 (en) | 2018-05-16 | 2021-02-09 | Cipla Limited | Depot formulation |
EP3806956A4 (en) | 2018-06-13 | 2022-08-10 | Zachriel Neurosciences, Llc | METHODS AND DOSAGE REGIMES FOR PREVENTING OR DELAYING THE ONSET OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT |
CN112057428B (zh) * | 2020-10-22 | 2022-06-24 | 上海翰森生物医药科技有限公司 | 一种酒石酸伐尼克兰的药物组合物及其制备方法 |
WO2022271600A1 (en) * | 2021-06-25 | 2022-12-29 | Handa Pharma, Inc. | Stable varenicline dosage forms |
AU2022326252A1 (en) * | 2021-08-07 | 2024-03-21 | Lupin Limited | Stabilized solid oral pharmaceutical composition of varenicline |
WO2023075826A1 (en) * | 2021-10-28 | 2023-05-04 | The Texas A&M University System | Compositions of stable metformin and similar drug products with control on nitroso impurities |
WO2023275413A2 (en) | 2021-12-23 | 2023-01-05 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
US11602537B2 (en) * | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9814592B1 (pt) * | 1997-12-31 | 2010-06-01 | composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento. | |
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
DE19845358A1 (de) * | 1998-10-02 | 2000-04-06 | Roehm Gmbh | Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe |
US6306436B1 (en) * | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
EA005529B1 (ru) * | 2001-05-14 | 2005-04-28 | Пфайзер Продактс Инк. | Цитрат 5,8,14-триазатетрацикло-(10.3.1.0.0)-гексадека-2(11),3,5,7,9-пентаена |
HU229867B1 (en) * | 2001-05-14 | 2014-10-28 | Pfizer Prod Inc | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
JP2005507411A (ja) * | 2001-10-31 | 2005-03-17 | ファイザー・プロダクツ・インク | 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。 |
WO2003045394A1 (en) * | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
CN1596128A (zh) * | 2001-11-30 | 2005-03-16 | 辉瑞产品公司 | 5,7,14-三氮杂四环[10.3.1.0(2,11).0(4,9)]-十六碳-2(11)3,5,7,9-五烯的药物组合物 |
-
2004
- 2004-05-07 BR BRPI0410219-3A patent/BRPI0410219A/pt not_active IP Right Cessation
- 2004-05-07 EP EP04731695A patent/EP1633358A1/en not_active Withdrawn
- 2004-05-07 JP JP2006530664A patent/JP2006528237A/ja not_active Withdrawn
- 2004-05-07 CA CA002525874A patent/CA2525874C/en not_active Expired - Fee Related
- 2004-05-07 WO PCT/IB2004/001613 patent/WO2004103372A1/en not_active Application Discontinuation
- 2004-05-07 MX MXPA05012507A patent/MXPA05012507A/es unknown
- 2004-05-18 AR ARP040101714A patent/AR044383A1/es unknown
- 2004-05-18 US US10/848,464 patent/US20040235850A1/en not_active Abandoned
- 2004-05-19 TW TW093114089A patent/TW200427469A/zh unknown
-
2007
- 2007-08-10 US US11/836,832 patent/US20080026059A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200427469A (en) | 2004-12-16 |
US20040235850A1 (en) | 2004-11-25 |
EP1633358A1 (en) | 2006-03-15 |
US20080026059A1 (en) | 2008-01-31 |
WO2004103372A1 (en) | 2004-12-02 |
BRPI0410219A (pt) | 2006-05-09 |
CA2525874C (en) | 2007-11-27 |
MXPA05012507A (es) | 2006-01-30 |
JP2006528237A (ja) | 2006-12-14 |
CA2525874A1 (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044383A1 (es) | Composiciones farmaceuticas de vareniclina | |
EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
CR9587A (es) | Derivados de piridazina | |
CY1118191T1 (el) | Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
AR060931A1 (es) | Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion | |
EE200300033A (et) | Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
NO20062513L (no) | Sammensetninger og doseringsformer for forsterket absorpsjon av metformin | |
CY1115825T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους | |
UY27870A1 (es) | Nuevos derivados de quinuclidina-amida | |
CR7718A (es) | Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso | |
DE69809074T2 (de) | Herstellung von arzneimitteln | |
UY28922A1 (es) | Ligandos del receptor cb1 útiles en el tratamiento de dolor y/u otros síntomas o enfermedades relacionadas; compuestos farmacéuticos y su preparación. | |
UY29427A1 (es) | Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones | |
NO20062004L (no) | Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav | |
IT1318625B1 (it) | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. | |
NO20025999D0 (no) | Klart, vandig anestetisk preparat | |
RS50768B (sr) | Režim doziranja i farmaceutska formulacija za urgentnu zaštitu | |
UY28536A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
WO2006053089A3 (en) | Methods and formulations for making pharmaceutical compositions containing bupropion | |
UY25356A1 (es) | Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
AR033403A1 (es) | Uso de reovirus para la fabricacion de un medicamento para reducir una masa tumoral solida. | |
ATE346592T1 (de) | Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor | |
BRPI0407335A (pt) | Agentes antibacterianos | |
AR053333A1 (es) | Composiciones farmaceuticas orales y parenterales que contienen altas concentraciones de agentes solubilizantes aromaticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |